{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:41:35Z","timestamp":1761460895663,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":4263,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.7861\/clinmedicine.12-4-357","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T18:27:28Z","timestamp":1361298448000},"page":"357-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Drug therapy of inflammatory arthritis"],"prefix":"10.1016","volume":"12","author":[{"given":"Nicola J","family":"Gullick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.7861\/clinmedicine.12-4-357_bib1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib2","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/1529-0131(199906)42:6<1232::AID-ANR21>3.0.CO;2-3","article-title":"Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging","volume":"42","author":"Backhaus","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.12-4-357_bib3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrrheum.2011.95","article-title":"Ultrasonography in inflammatory rheumatic disease: an overview","volume":"7","author":"Schirmer","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.7861\/clinmedicine.12-4-357_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/BOR.0b013e328339381e","article-title":"Magnetic resonance imaging in spondyloarthritis","volume":"22","author":"Marzo-Ortega","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.7861\/clinmedicine.12-4-357_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrrheum.2011.76","article-title":"Anti-CCP antibodies: the past, the present and the future","volume":"7","author":"van Venrooij","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.7861\/clinmedicine.12-4-357_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.2005.041129","article-title":"Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.7861\/clinmedicine.12-4-357_bib7","first-page":"CD","article-title":"Opioid therapy for treating rheumatoid arthritis pain","author":"Whittle","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.7861\/clinmedicine.12-4-357_bib8","first-page":"CD","article-title":"Neuromodulators for pain management in rheumatoid arthritis","author":"Richards","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.7861\/clinmedicine.12-4-357_bib9","first-page":"CD","article-title":"Antidepressants for pain management in rheumatoid arthritis","author":"Richards","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.7861\/clinmedicine.12-4-357_bib10","first-page":"CD","article-title":"Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)","author":"Ramiro","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.7861\/clinmedicine.12-4-357_bib11","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/ard.2009.127225","article-title":"Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Gaujoux-Viala","year":"2010","journal-title":"Ann Rheum Dis"},{"year":"2009","series-title":"Rheumatoid arthritis. Clinical guideline 79","key":"10.7861\/clinmedicine.12-4-357_bib12"},{"key":"10.7861\/clinmedicine.12-4-357_bib13","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/rheumatology\/kei031","article-title":"A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal","volume":"44","author":"Choy","year":"2005","journal-title":"Rheumatology (Oxford)"},{"year":"2012","series-title":"A randomized placebo-controlled trial of MTX in PsA Rheumatology","author":"Kingsley","key":"10.7861\/clinmedicine.12-4-357_bib14"},{"key":"10.7861\/clinmedicine.12-4-357_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib16","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/eye.2000.84","article-title":"Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis","volume":"14","author":"Benitez-Del-Castillo","year":"2000","journal-title":"Eye"},{"issue":"1","key":"10.7861\/clinmedicine.12-4-357_bib17","first-page":"CD","article-title":"Effects of glucocorticoids on radiological progression in rheumatoid arthritis","author":"Kirwan","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.7861\/clinmedicine.12-4-357_bib18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2003.014050","article-title":"Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial","volume":"63","author":"Capell","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(08)60132-4","article-title":"Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial","volume":"371","author":"Buttgereit","year":"2008","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.12-4-357_bib20","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1503\/cmaj.091391","article-title":"A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview","volume":"181","author":"Singh","year":"2009","journal-title":"Can Med Assoc J"},{"key":"10.7861\/clinmedicine.12-4-357_bib21","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/art.22805","article-title":"Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2","volume":"56","author":"van der Heijde","year":"2007","journal-title":"Arthritis Rheum"},{"year":"2010","series-title":"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. Technology appraisal 199","key":"10.7861\/clinmedicine.12-4-357_bib22"},{"year":"2008","series-title":"Adalimumab, etanercept and infliximab for ankylosing spondylitis. Technology appraisal 143","key":"10.7861\/clinmedicine.12-4-357_bib23"},{"key":"10.7861\/clinmedicine.12-4-357_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/ar67","article-title":"Mechanisms of bone loss in inflammatory arthritis","volume":"2","author":"Goldring","year":"2000","journal-title":"Arthritis Res"},{"key":"10.7861\/clinmedicine.12-4-357_bib25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/ard.2006.068015","article-title":"Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis","volume":"67","author":"Steen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/pgmj.2005.039586","article-title":"Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy?","volume":"82","author":"Adabayo","year":"2009","journal-title":"J Postgrad Med"},{"key":"10.7861\/clinmedicine.12-4-357_bib27","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/00365520510023846","article-title":"Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden","volume":"40","author":"Bjornsson","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"10.7861\/clinmedicine.12-4-357_bib28","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.23913","article-title":"Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis","volume":"59","author":"Lacaille","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.12-4-357_bib29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","article-title":"Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.7861\/clinmedicine.12-4-357_bib30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MD.0b013e318211106a","article-title":"TNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis","volume":"90","author":"Lane","year":"2011","journal-title":"Medicine"},{"key":"10.7861\/clinmedicine.12-4-357_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Saillot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib33","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"10.7861\/clinmedicine.12-4-357_bib34","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/rheumatology\/35.8.738","article-title":"Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study","volume":"35","author":"Jones","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.7861\/clinmedicine.12-4-357_bib35","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.12-4-357_bib36","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.7861\/clinmedicine.12-4-357_bib37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib38","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/ard.2009.123976","article-title":"Evidence for treating rheumatoid arthritis to target: results of a systematic literature search","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib39","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/ard.2009.108027","article-title":"Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis","volume":"69","author":"van Tuyl","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/rheumatology\/kem288","article-title":"Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis","volume":"47","author":"Verschueren","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.7861\/clinmedicine.12-4-357_bib41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/rheumatology\/ker399","article-title":"Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years","volume":"51","author":"Gullick","year":"2012","journal-title":"Rheumatology (Oxford)"},{"year":"2010","series-title":"Tight control of psoriatic arthritis (TICOPA)","key":"10.7861\/clinmedicine.12-4-357_bib42"},{"key":"10.7861\/clinmedicine.12-4-357_bib43","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1529-8019.2008.01216.x","article-title":"New biologics for psoriasis and psoriatic arthritis","volume":"22","author":"Rozenblit","year":"2009","journal-title":"Dermatol Ther"},{"key":"10.7861\/clinmedicine.12-4-357_bib45","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.7861\/clinmedicine.12-4-357_bib46","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/ard.2010.145946","article-title":"Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib47","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.27383","article-title":"Different response to rituximab in tumor necrosis factor blocker\u2013naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial","volume":"62","author":"Song","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.12-4-357_bib48","first-page":"233","article-title":"Promising new treatments for rheumatoid arthritis: the kinase inhibitors","volume":"69","author":"Yazici","year":"2011","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib49","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib51","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-357_bib50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147021182402284X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147021182402284X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmedicine.12-4-357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:36:51Z","timestamp":1761460611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147021182402284X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S147021182402284X"],"URL":"https:\/\/doi.org\/10.7861\/clinmedicine.12-4-357","relation":{},"ISSN":["1470-2118"],"issn-type":[{"type":"print","value":"1470-2118"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug therapy of inflammatory arthritis","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmedicine.12-4-357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2012. All rights reserved.","name":"copyright","label":"Copyright"}]}}